Clear Street Lifts Price Target on Editas (EDIT) Medicine Amid Pipeline Progress
Editas Medicine (NASDAQ:EDIT) is one of the best gene-editing stocks to buy according to hedge funds.
Editas Medicine Inc. (EDIT)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | ADAR1 Capital Management Daniel Schneeberger | 8,889,000 | $28,800,360 | 1.32% | |
| 2. | RA Capital Management Peter Kolchinsky | 8,889,000 | $28,800,360 | 0.25% | |
| 3. | Commodore Capital Egen Atkinson And Michael Kramarz | 8,889,000 | $28,800,360 | 1.72% | |
| 4. | Paradigm Biocapital Advisors Senai Asefaw | 5,586,625 | $18,100,665 | 0.34% | |
| 5. | Opaleye Management James A. Silverman | 3,861,930 | $12,512,653 | +101% | 1.13% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $5.64 | 45,000 | $253,867.50 | 67,700 | 2024-05-13 | Filing | |
| $45.51 | 5,800 | $263,969.60 | 22,700 | 2021-03-03 | Filing | |
| $46.27 | 25,000 | $1,156,800.00 | 35,000 | 2021-03-02 | Filing | |
| $23.94 | 10,200 | $244,188.00 | 16,900 | 2019-03-05 | Filing | |
| $38.03 | 10,000 | $380,252.00 | 10,000 | 2018-05-18 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.04 | 709 | $2,153.37 | 61,660 | 2026-09-03 | Filing | |
| $3.04 | 453 | $1,375.85 | 13,839 | 2026-09-03 | Filing | |
| $3.04 | 5,124 | $15,562.61 | 243,189 | 2026-09-03 | Filing | |
| $2.58 | 678 | $1,749.24 | 14,292 | 2026-08-03 | Filing | |
| $2.67 | 4,928 | $13,157.76 | 62,369 | 2026-07-28 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 65,291 | $167,798 | 0% | |
| 2. | 64,022 | $165,817 | 0.01% | |
| 3. | 39,243 | $111,450 | 0% | |
| 4. | 33,500 | $86,095 | 0.01% | |
| 5. | 10,000 | $76,122 | 0% |
News See All
9 Best Gene-Editing Stocks to Buy According to Hedge Funds
In this article, we will take a look at the 9 Best Gene-Editing Stocks to Buy According to Hedge Funds.
Editas Medicine Inc. (EDIT) Confirms EDT-401 as Lead Vivo Program
Editas Medicine Inc. (NASDAQ:EDIT) is one of the best performing penny stocks to buy now. On September 5, HC Wainwright reiterated a “Buy” rating on the stock and a $5 price target.
10 Best Performing Penny Stocks to Buy Now
In this article, we will be taking a look at the 10 Best Performing Penny Stocks to Buy Now. Long-lagging small-cap and penny stocks are increasingly capturing the attention of value investors.
Editas Surpasses Therapeutic Gene Editing Threshold in New Preclinical Data
Editas Medicine, Inc. (NASDAQ:EDIT) ranks among the best CRISPR stocks to buy. At the European Hematology Association 2025 Congress on June 12, Editas Medicine, Inc.
Top 10 CRISPR Stocks to Buy Now
In this article, we will take a look at the Top 10 CRISPR Stocks to Buy Now.
Top 11 CRISPR Stocks to Invest In
In this article, we will take a look at the Top 11 CRISPR Stocks to Invest in.
10 Most Promising Gene Editing Stocks to Buy According to Hedge Funds
In this article, we will take a look at the 10 Most Promising Gene Editing Stocks to Buy According to Hedge Funds.
Editas Medicine, Inc. (NASDAQ:EDIT) Q2 2024 Earnings Call Transcript
Editas Medicine, Inc. (NASDAQ:EDIT) Q2 2024 Earnings Call Transcript August 7, 2024Editas Medicine, Inc. misses on earnings expectations. Reported EPS is $-0.82137 EPS, expectations were $-0.69.
Top 10 Small-Cap Stocks with Highest Upside Potential
In this article, we'll list the top 10 small-cap stocks with the highest upside potential. Small-cap stocks are companies with a market capitalization of somewhere between $250 million and $2 billion.
Hedge Fund Resource Center